Erasca Corp (ERAS): Earnings growth forecast for next year
Erasca, Inc. (ERAS) ensures research accuracy through strict climate control during the transport of biomaterials. The company's strategy aims to eradicate RAS mutations via the launch of the blockbuster naporafenib. Analyst 12-month EPS growth targets confirm this trajectory, with the 36.70 mark serving as a key metric. The financial model is based on investments prior to the commercialization of targeted cancer therapies.
ERAS (erasca.com): analytical breakdowns and indicator data
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- book capitalization indicators:
- issuer credit burden and liquidity indicators:
- net income and valuation ratios data:
ERAS - Net Financial Result|Expected Profit Erasca, Inc.|ERAS - Price to Earnings Multiple|Forward P/E Multiple Erasca, Inc.|ERAS - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio Erasca|ERAS - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Erasca|ERAS - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months erasca.com|ERAS - Earnings per share increase in current year|Earnings growth forecast for next year Erasca, Inc.
Comprehensive company analysis:Erasca Corp, ERAS
This indicator measures the expected growth rate of earnings per share, reflecting consolidated analyst forecasts regarding future profitability. Comparing this parameter with industry peers via the projected EPS growth rate for next year allows for an assessment of the asset's capitalization potential. The metric's trend signals market expectations for business efficiency. For Erasca, Inc. (ERAS), such forecasts depend on the success of clinical trials delegated to external contractors to minimize operational risks.
Main competitors
ONC (BeiGene Corp) - Earnings growth forecast for next year|Expected net earnings per share growth next year Halozyme Corp HALO|Earnings growth forecast for next year RVMD|AAPG - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year CG Oncology CGON|Expected earnings per share trend next year URGN|Bicara Bio - Earnings growth forecast for next year|PSNL - Earnings growth forecast for next year|Delcath Systems, Inc. (DCTH) - Net earnings per share growth forecast for next year|YMAB - Consensus forecast of earnings per share growth for next year|AURA (Aura Biosciences) - Earnings growth forecast for next year|Expected earnings per share growth for next year Candel (CADL)|Earnings growth forecast for next year ARAY|Earnings growth forecast for next year sellaslifesciences.com (SLS)|Actuate Therapeutics, Inc. - Expected earnings per share growth for next year|Expected earnings per share trend next year CTOR|TuHURA - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year Protara Therapeutics Inc TARA|Fate Therapeutics Corp (FATE) - Net earnings per share growth forecast for next year|Projected earnings per share growth rate for next year WHWK|TCRX (TScan Therapeutics Inc) - Earnings growth forecast for next year|Expected earnings per share growth for next year Champions Oncology Corp (CSBR)|Expected earnings per share growth for next year XBIT (XBiotech Inc.)|Consensus forecast of earnings per share growth for next year cel-sci.com|Earnings growth forecast for next year OSTX (OS Therapies Inc)|radiopharmtheranostics.com (RADX) - Expected net earnings per share growth next year|ARTV - Net earnings per share growth forecast for next year|Expected earnings per share trend next year ANL (Adlai Nortye Ltd.)|VERU: Earnings growth forecast for next year|Tempest Therapeutics Inc (TPST) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year Xilio Therapeutics Inc|Enochian BioSciences (RENB) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year MURA|Expected earnings per share growth for next year kairospharma.com KAPA|Earnings growth forecast for next year OKUR (OnKure Therapeutics)|Earnings growth forecast for next year CytoMed Therapeutics Ltd GDTC|CRIS - Net earnings per share growth forecast for next year|APLM (Apollomics, Inc.) - Projected earnings per share growth rate for next year|THAR: Earnings growth forecast for next year|Expected earnings per share growth for next year Advanced Biomed|GNPX (Genprex) - Earnings growth forecast for next year|Expected net earnings per share growth next year Calidi Bio CLDI|Net earnings per share growth forecast for next year Sunshine Biopharma, Inc. (SBFM)|XBIO (xeneticbio.com) - Expected earnings per share trend next year|Salarius Pharmaceuticals - Expected earnings per share growth for next year|Expected earnings per share trend next year PPBT|AON - Earnings growth forecast for next year|BeiGene Ltd. (BGNE) - Expected earnings per share growth for next year|CKPT (Checkpoint Therapeutics, Inc) - Expected earnings per share growth for next year|elevationoncology.com (ELEV) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year iCAD Inc.|IKNA: Expected earnings per share trend next year|Earnings growth forecast for next year NTBL|VIRX - Expected net earnings per share growth next year|Earnings growth forecast for next year MOR (MorphoSys Corp)|NAYA Biosciences Corp (NAYA) - Expected net earnings per share growth next year|AAPGV - Net earnings per share growth forecast for next year
